(-0.11%) 5 463.42 points
(-0.32%) 38 986 points
(0.24%) 17 761 points
(0.38%) $81.14
(-3.48%) $2.66
(-0.95%) $2 308.70
(-0.41%) $28.75
(1.46%) $1 000.80
(0.28%) $0.936
(0.78%) $10.69
(0.41%) $0.791
(-0.25%) $87.28
Live Chart Being Loaded With Signals
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company\'s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach...
Stats | |
---|---|
本日の出来高 | 1.79M |
平均出来高 | 725 973 |
時価総額 | 0.00 |
EPS | $-0.550 ( Q3 | 2022-11-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.69 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.438 (3.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-30 | Walker Paul Edward | Sell | 4 294 207 | Common Stock |
2022-11-30 | Sonsini Peter W. | Sell | 4 294 207 | Common Stock |
2022-11-30 | Sandell Scott D | Sell | 4 294 207 | Common Stock |
2022-12-01 | Mathers Edward T | Sell | 16 000 | Stock Option (right to buy) |
2022-11-30 | Makhzoumi Mohamad | Sell | 4 294 207 | Common Stock |
INSIDER POWER |
---|
-17.62 |
Last 97 transactions |
Buy: 48 602 836 | Sell: 208 882 585 |
ボリューム 相関
Akouos, Inc. 相関 - 通貨/商品
Akouos, Inc. 財務諸表
Annual | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.94 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.94 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.77 |
FY | 2019 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.65 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Akouos, Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company\'s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。